Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

ClinicalTrials.gov ID: NCT04882124

Public ClinicalTrials.gov record NCT04882124. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Study identification

NCT ID
NCT04882124
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
38 participants

Conditions and interventions

Interventions

  • CSJ117 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 23, 2021
Primary completion
Sep 14, 2022
Completion
Sep 14, 2022
Last update posted
Nov 27, 2022

2021 – 2022

United States locations

U.S. sites
7
U.S. states
4
U.S. cities
7
Facility City State ZIP Site status
Novartis Investigative Site Andalusia Alabama 36420
Novartis Investigative Site Crowley Louisiana 70526
Novartis Investigative Site New Orleans Louisiana 70115
Novartis Investigative Site Saint Charles Missouri 63301
Novartis Investigative Site St Louis Missouri 63141
Novartis Investigative Site Huntersville North Carolina 28078
Novartis Investigative Site Shelby North Carolina 28150

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04882124, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 27, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04882124 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →